DK3418300T3 - Neutralisering af anti-influenza-a-virusantistoffer og anvendelser deraf - Google Patents
Neutralisering af anti-influenza-a-virusantistoffer og anvendelser deraf Download PDFInfo
- Publication number
- DK3418300T3 DK3418300T3 DK18180926.0T DK18180926T DK3418300T3 DK 3418300 T3 DK3418300 T3 DK 3418300T3 DK 18180926 T DK18180926 T DK 18180926T DK 3418300 T3 DK3418300 T3 DK 3418300T3
- Authority
- DK
- Denmark
- Prior art keywords
- influenza
- neutralization
- virus antibodies
- antibodies
- virus
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title 1
- 206010022000 influenza Diseases 0.000 title 1
- 238000006386 neutralization reaction Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18180926.0A EP3418300B1 (en) | 2011-07-18 | 2011-07-18 | Neutralizing anti-influenza a virus antibodies and uses thereof |
| EP11784765.7A EP2734545B1 (en) | 2011-07-18 | 2011-07-18 | Neutralizing anti-influenza a virus antibodies and uses thereof |
| PCT/IB2011/002329 WO2013011347A1 (en) | 2011-07-18 | 2011-07-18 | Neutralizing anti-influenza a virus antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3418300T3 true DK3418300T3 (da) | 2020-12-07 |
Family
ID=44993618
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18180926.0T DK3418300T3 (da) | 2011-07-18 | 2011-07-18 | Neutralisering af anti-influenza-a-virusantistoffer og anvendelser deraf |
| DK11784765.7T DK2734545T3 (da) | 2011-07-18 | 2011-07-18 | Neutraliserende anti-influenza a-virusantistoffer og anvendelser deraf |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11784765.7T DK2734545T3 (da) | 2011-07-18 | 2011-07-18 | Neutraliserende anti-influenza a-virusantistoffer og anvendelser deraf |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9587010B2 (da) |
| EP (3) | EP3418300B1 (da) |
| JP (1) | JP6035332B2 (da) |
| CN (1) | CN103717617B (da) |
| AU (1) | AU2011373387B2 (da) |
| CA (1) | CA2841551C (da) |
| DK (2) | DK3418300T3 (da) |
| ES (2) | ES2841899T3 (da) |
| HR (2) | HRP20190714T1 (da) |
| HU (2) | HUE044089T2 (da) |
| LT (2) | LT2734545T (da) |
| MX (1) | MX352338B (da) |
| PL (2) | PL3418300T3 (da) |
| SI (2) | SI2734545T1 (da) |
| WO (1) | WO2013011347A1 (da) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
| WO2010009271A2 (en) | 2008-07-15 | 2010-01-21 | Academia Sinica | Glycan arrays on ptfe-like aluminum coated glass slides and related methods |
| US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
| WO2011143262A2 (en) | 2010-05-10 | 2011-11-17 | Sinica, Academia | Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses |
| CN107417789A (zh) * | 2011-07-18 | 2017-12-01 | 生物医学学会 | 中和抗甲型流感病毒抗体及其用途 |
| HUE044089T2 (hu) | 2011-07-18 | 2019-09-30 | Inst Res Biomedicine | Neutralizáló anti-influenza A antitestek és alkalmazásaik |
| US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| WO2014031498A1 (en) | 2012-08-18 | 2014-02-27 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
| WO2014031762A1 (en) | 2012-08-21 | 2014-02-27 | Academia Sinica | Benzocyclooctyne compounds and uses thereof |
| CN104968367B (zh) | 2012-11-13 | 2018-04-13 | 弗·哈夫曼-拉罗切有限公司 | 抗血凝素抗体和使用方法 |
| KR20140118682A (ko) * | 2013-03-29 | 2014-10-08 | (주)셀트리온 | 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물 |
| EP3013365B1 (en) | 2013-06-26 | 2019-06-05 | Academia Sinica | Rm2 antigens and use thereof |
| EP3013347B1 (en) | 2013-06-27 | 2019-12-11 | Academia Sinica | Glycan conjugates and use thereof |
| CN105682666B (zh) | 2013-09-06 | 2021-06-01 | 中央研究院 | 使用醣脂激活人类iNKT细胞 |
| ES2837392T3 (es) * | 2013-10-02 | 2021-06-30 | Medimmune Llc | Anticuerpos anti-influenza A neutralizantes y usos de los mismos |
| WO2015109180A2 (en) | 2014-01-16 | 2015-07-23 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| EP4043489A1 (en) * | 2014-03-19 | 2022-08-17 | Dana-Farber Cancer Institute, Inc. | Immunogenetic restriction on elicitation of antibodies |
| TWI797430B (zh) | 2014-03-27 | 2023-04-01 | 中央研究院 | 反應性標記化合物及其用途 |
| WO2015166329A1 (en) | 2014-05-01 | 2015-11-05 | Indian Institute Of Science | Polypeptides for generating anti-influenza antibodies and uses thereof |
| CA2950415A1 (en) | 2014-05-27 | 2015-12-03 | Academia Sinica | Anti-cd20 glycoantibodies and uses thereof |
| US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| KR102576850B1 (ko) | 2014-05-27 | 2023-09-11 | 아카데미아 시니카 | 박테로이드 기원의 푸코시다제 및 이의 사용 방법 |
| JP7062361B2 (ja) | 2014-05-27 | 2022-05-06 | アカデミア シニカ | 抗ｈｅｒ２糖操作抗体群およびその使用 |
| KR102494193B1 (ko) | 2014-05-28 | 2023-01-31 | 아카데미아 시니카 | 항-ｔｎｆ-알파 글리코항체 및 이의 용도 |
| CA2954780A1 (en) | 2014-07-15 | 2016-01-21 | Medimmune, Llc | Neutralizing anti-influenza b antibodies and uses thereof |
| JP6899321B2 (ja) | 2014-09-08 | 2021-07-07 | アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ | 糖脂質を使用するヒトｉＮＫＴ細胞活性化 |
| TWI701258B (zh) | 2014-12-19 | 2020-08-11 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
| US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| TWI736523B (zh) | 2015-01-24 | 2021-08-21 | 中央研究院 | 新穎聚醣結合物及其使用方法 |
| SG11201705614QA (en) | 2015-02-05 | 2017-08-30 | Janssen Vaccines & Prevention Bv | Binding molecules directed against influenza hemagglutinin and uses thereof |
| GB201502137D0 (en) * | 2015-02-09 | 2015-03-25 | Ucl Business Plc | Treatment |
| CN107750253B (zh) | 2015-04-08 | 2022-10-04 | 达纳－法伯癌症研究所公司 | 人源化流感单克隆抗体及其使用方法 |
| AU2016271323B2 (en) | 2015-06-01 | 2022-08-25 | Medimmune, Llc | Neutralizing anti-influenza binding molecules and uses thereof |
| WO2017083627A1 (en) | 2015-11-13 | 2017-05-18 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| CN116271017A (zh) | 2016-01-13 | 2023-06-23 | 免疫医疗有限责任公司 | 治疗甲型流感的方法 |
| CN109195629A (zh) | 2016-02-24 | 2019-01-11 | 威特拉公司 | 流行性感冒抗体分子制剂 |
| JP2019515876A (ja) | 2016-03-08 | 2019-06-13 | アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ | Ｎ−グリカンおよびそのアレイのモジュール合成のための方法 |
| WO2017192589A1 (en) * | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
| SG10202011021XA (en) * | 2016-05-05 | 2020-12-30 | Univ Pennsylvania | Dna monoclonal antibodies targeting influenza virus |
| EP3500594A4 (en) | 2016-08-22 | 2020-03-11 | Cho Pharma Inc. | ANTIBODIES, BINDING FRAGMENTS AND METHOD FOR USE |
| WO2018038096A1 (ja) * | 2016-08-23 | 2018-03-01 | 国立大学法人東京大学 | モノクローナル抗体又はその抗原結合フラグメント及びその使用 |
| CN107868121B (zh) * | 2016-09-28 | 2021-03-16 | 中国医学科学院病原生物学研究所 | H3亚型流感病毒血凝素特异性保守表位、其抗体及其应用 |
| EP3574008B1 (en) * | 2017-01-27 | 2023-11-08 | National Research Council of Canada | Hemagglutinin-specific antibodies and uses thereof |
| EP3946613A1 (en) | 2019-03-25 | 2022-02-09 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| WO2021055798A1 (en) * | 2019-09-19 | 2021-03-25 | Duke University | Influenza neutralizing antibodies and their uses |
| US20220267382A1 (en) * | 2019-09-20 | 2022-08-25 | Academia Sinica | Chimeric hemagglutinin protein and a vaccine composition comprising the same |
| IL293804A (en) | 2019-12-11 | 2022-08-01 | Visterra Inc | Anti-hemagglutinin (ha) antibody molecules, preparations containing them and their uses |
| CN118613502A (zh) * | 2021-11-05 | 2024-09-06 | 丹娜-法伯癌症研究所 | 人广谱交叉反应性流感单克隆抗体及其使用方法 |
| CN117430664B (zh) * | 2023-10-24 | 2024-04-09 | 暨南大学附属第六医院(东莞市东部中心医院) | 一种甲型流感病毒t细胞抗原表位肽及其应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB819376A (en) | 1956-10-20 | 1959-09-02 | Colne Switchgear K & W Ltd | Improvements in electro-magnetic overload units for electrical apparatus |
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| AU8063798A (en) | 1997-06-19 | 1999-01-04 | Regents Of The University Of California, The | Secretory immunoglobulin produced by single cells and methods for making and using same |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| JP4656478B2 (ja) | 2000-02-22 | 2011-03-23 | 株式会社医学生物学研究所 | 抗体ライブラリー |
| WO2004007667A2 (en) | 2002-07-11 | 2004-01-22 | The General Hospital Corporation | Polynucleotide and polypeptide fat metabolism regulators and uses thereof |
| AU2004215125B2 (en) | 2003-02-26 | 2011-01-06 | Institute For Research In Biomedicine | Monoclonal antibody production by EBV transformation of B cells |
| CN1756562A (zh) * | 2003-03-07 | 2006-04-05 | 麦克公司 | 流感病毒疫苗 |
| JP4817625B2 (ja) * | 2003-08-11 | 2011-11-16 | 一般財団法人阪大微生物病研究会 | 粘膜免疫誘導アジュバントを含む新規ワクチン |
| WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| KR20080049113A (ko) | 2005-10-21 | 2008-06-03 | 노파르티스 아게 | Ｉｌ-13에 대항한 인간 항체 및 치료적 용도 |
| TWI477602B (zh) | 2006-02-09 | 2015-03-21 | Educational Foundation Jichi Medical Univ | Novel viral vector |
| WO2007134327A2 (en) | 2006-05-15 | 2007-11-22 | Sea Lane Biotechnologies, Llc. | Neutralizing antibodies to influenza viruses |
| EP2450377A1 (en) | 2006-09-07 | 2012-05-09 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof |
| CN101541832B (zh) * | 2006-09-07 | 2014-11-12 | 克鲁塞尔荷兰公司 | 能中和流感病毒h5n1的人结合分子及其应用 |
| DK2769992T3 (da) | 2006-10-02 | 2021-03-22 | Regeneron Pharma | Humane antistoffer med høj affinitet for human IL-4-receptor |
| JP5601836B2 (ja) | 2006-11-08 | 2014-10-08 | マクロジェニックス ウエスト， インコーポレイテッド | Ｔｅｓ７およびｔｅｓ７に結合する抗体 |
| EP1925318A1 (en) | 2006-11-20 | 2008-05-28 | Paul-Ehrlich-Institut | Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
| US8124092B2 (en) | 2007-03-13 | 2012-02-28 | Institute For Research In Biomedicine | Antibodies against H5N1 strains of influenza A virus |
| EA034733B1 (ru) | 2008-01-21 | 2020-03-13 | Медикаго Инк. | Нуклеиновая кислота для увеличенной экспрессии гемагглютинина вируса гриппа в растении и ее применение |
| ITTO20080204A1 (it) | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a |
| MX2011000768A (es) | 2008-07-25 | 2011-10-05 | Inst Research In Biomedicine | Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos. |
| DK2350128T3 (da) | 2008-10-22 | 2014-12-01 | Inst Research In Biomedicine | Fremgangsmåder til fremstilling af antistoffer fra plasmaceller |
| JP2012521786A (ja) | 2009-03-30 | 2012-09-20 | モウント シナイ スクール オフ メディシネ | インフルエンザウイルスワクチン及びその使用 |
| NZ597401A (en) | 2009-06-24 | 2013-09-27 | Medicago Inc | Chimeric influenza virus-like particles comprising hemagglutinin |
| HUE044089T2 (hu) * | 2011-07-18 | 2019-09-30 | Inst Res Biomedicine | Neutralizáló anti-influenza A antitestek és alkalmazásaik |
-
2011
- 2011-07-18 HU HUE11784765A patent/HUE044089T2/hu unknown
- 2011-07-18 MX MX2014000749A patent/MX352338B/es active IP Right Grant
- 2011-07-18 PL PL18180926T patent/PL3418300T3/pl unknown
- 2011-07-18 PL PL11784765T patent/PL2734545T3/pl unknown
- 2011-07-18 LT LTEP11784765.7T patent/LT2734545T/lt unknown
- 2011-07-18 HU HUE18180926A patent/HUE051756T2/hu unknown
- 2011-07-18 CN CN201180072356.0A patent/CN103717617B/zh active Active
- 2011-07-18 LT LTEP18180926.0T patent/LT3418300T/lt unknown
- 2011-07-18 EP EP18180926.0A patent/EP3418300B1/en active Active
- 2011-07-18 WO PCT/IB2011/002329 patent/WO2013011347A1/en active Application Filing
- 2011-07-18 AU AU2011373387A patent/AU2011373387B2/en active Active
- 2011-07-18 US US14/233,719 patent/US9587010B2/en active Active
- 2011-07-18 JP JP2014520738A patent/JP6035332B2/ja active Active
- 2011-07-18 ES ES18180926T patent/ES2841899T3/es active Active
- 2011-07-18 SI SI201131700T patent/SI2734545T1/sl unknown
- 2011-07-18 ES ES11784765T patent/ES2732552T3/es active Active
- 2011-07-18 DK DK18180926.0T patent/DK3418300T3/da active
- 2011-07-18 DK DK11784765.7T patent/DK2734545T3/da active
- 2011-07-18 SI SI201131938T patent/SI3418300T1/sl unknown
- 2011-07-18 CA CA2841551A patent/CA2841551C/en active Active
- 2011-07-18 EP EP11784765.7A patent/EP2734545B1/en active Active
- 2011-07-18 EP EP20200200.2A patent/EP3812397A1/en active Pending
-
2017
- 2017-01-20 US US15/411,677 patent/US20170204167A1/en not_active Abandoned
-
2018
- 2018-11-01 US US16/178,497 patent/US10815294B2/en active Active
-
2019
- 2019-04-16 HR HRP20190714TT patent/HRP20190714T1/hr unknown
-
2020
- 2020-12-10 HR HRP20201975TT patent/HRP20201975T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3418300T3 (da) | Neutralisering af anti-influenza-a-virusantistoffer og anvendelser deraf | |
| DK2691443T3 (da) | Konjugerede lipomerer og anvendelser af disse | |
| CY2017025I2 (el) | Αντιδοτα αντιπηκτικων | |
| DK2771364T3 (da) | Fremstilling af heterodimere proteiner | |
| DK2794654T3 (da) | Anti-phf-tau-antistoffer og deres anvendelser | |
| DK3556774T3 (da) | Anti-CD40-antistoffer og anvendelser deraf | |
| DK3199552T3 (da) | Anti-ceacam5-antistoffer og anvendelser heraf | |
| DK2806892T3 (da) | Kombineret terapeutisk anvendelse af antistoffer og endoglycosidaser | |
| DK2785375T3 (da) | Anti-pd-l1-antistoffer og anvendelser deraf | |
| BR112014012137A2 (pt) | anticorpos anti-fgfr2 e suas utilizações | |
| CO7020859A2 (es) | Anticuerpos anti-cd134 (ox40) y usos de los mismos | |
| CO6821892A2 (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| DK2914291T3 (da) | Anti-komplement-c1s-antistoffer og anvendelser deraf | |
| CO7010824A2 (es) | Inhibidores de aplicación viral | |
| DK3339323T3 (da) | Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf | |
| DK2914627T3 (da) | Anti-cd40-antistoffer og fremgangsmåder til anvendelse | |
| CO6940383A2 (es) | Anticuerpos anti-erbb3 y usos de los mismos | |
| DK2776567T3 (da) | Sammensætninger og fremgangsmåder til behandling af cytomegalovirus. | |
| DK3333188T3 (da) | Anti-NGF-antistoffer og deres anvendelse | |
| DK2931891T3 (da) | Rna-styret modificering af menneskelige genomer | |
| DK2609956T3 (da) | Midlertidigt foldbart kateteraggregat og dertil hørende fremgangsmåde | |
| DK3381943T3 (da) | Anti-kit-antistoffer og anvendelser deraf | |
| DK3495392T3 (da) | Anti-cgrp-sammensætninger og anvendelse deraf | |
| CO7020870A2 (es) | Anticuerpos anti-htra1 y métodos de uso | |
| DK2717941T3 (da) | Behandling af cancer |